Trial Profile
Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2022 The dose of Bevacizumab for cohort 1 and cohort 2 was changed from 5mg to 10 mg (cohort 1) and from 10 mg to 15mg (cohort2) respectively.
- 08 Jul 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Results of phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma has been published in the Journal of Clinical Oncology.